Evercore ISI Group Maintains Outperform on Krystal Biotech, Raises Price Target to $206
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group maintains an Outperform rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $201 to $206.
August 12, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group maintains an Outperform rating on Krystal Biotech and raises the price target from $201 to $206.
The raised price target and maintained Outperform rating from a reputable analyst firm like Evercore ISI Group is likely to positively impact investor sentiment and drive short-term price appreciation for Krystal Biotech.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100